利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

39 条记录 (耗时 0.035 秒)

    High affinity antibodies against HMGB1 and methods of use thereof
    11.
    发明授权
    High affinity antibodies against HMGB1 and methods of use thereof 失效
    针对HMGB1的高亲和力抗体及其使用方法

    公开(公告)号：US08153131B2

    公开(公告)日：2012-04-10

    申请号：US12534217

    申请日：2009-08-03

    申请人： Herren Wu ,  Christian Allan ,  Changshou Gao ,  Ling-Ling An ,  Peter Kiener ,  Su-Yau Mao ,  Anthony Coyle

    发明人： Herren Wu ,  Christian Allan ,  Changshou Gao ,  Ling-Ling An ,  Peter Kiener ,  Su-Yau Mao ,  Anthony Coyle

    IPC分类号： A61K39/395

    CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  Y02A50/412

    摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

    摘要翻译： 公开了用于抑制促炎细胞因子从脊椎动物细胞中释放并抑制患者炎性细胞因子级联的组合物和方法。 组合物包含例如特异性结合HMG1的高亲和力抗体及其抗原性片段。 本发明的高亲和力抗体和包含其的药物组合物可用于许多目的，例如作为针对广泛范围的炎性疾病和病症的治疗剂，例如败血症，类风湿性关节炎，腹膜炎，克罗恩病，再灌注损伤，败血症 内毒素性休克，囊性纤维化，心内膜炎，牛皮癣，牛皮癣关节炎，关节炎，过敏性休克，器官缺血，再灌注损伤和同种异体移植排斥。 此外，本发明的高亲和力抗体可用作诊断抗体。

    INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
    15.
    发明申请
    INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS 审中-公开
    干扰素诱导的药物动力学标记

    公开(公告)号：US20100261172A1

    公开(公告)日：2010-10-14

    申请号：US12598526

    申请日：2008-05-05

    申请人： Yihong Yao ,  Bahija Jallal ,  Ricardo Cibotti ,  Anthony Coyle ,  Peter Kiener

    发明人： Yihong Yao ,  Bahija Jallal ,  Ricardo Cibotti ,  Anthony Coyle ,  Peter Kiener

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q1/6851 ,  C12Q2600/106

    摘要： The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.

    摘要翻译： 本发明包括I型IFN和IFNα诱导的PD标志物表达谱，试剂盒和用于鉴定这种IFNα诱导的PD标志物表达谱的方法。 I型IFN和IFNα诱导的PD标志物表达谱也可用于例如治疗患有I型IFN或IFNα介导的病症的患者的方法，监测接受治疗的患者的疾病进展的方法 结合并调节IFNα活性的试剂，将患者鉴定为接受结合并中和IFNα活性的治疗剂的候选物，以及诊断或提供具有IFNα诱导的病症的患者的预后。

    INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
    16.
    发明申请
    INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS 审中-公开
    干扰素诱导的药物动力学标记

    公开(公告)号：US20100143372A1

    公开(公告)日：2010-06-10

    申请号：US12517333

    申请日：2007-12-06

    申请人： Yihong Yao ,  Bahija Jallal ,  Ricardo Cibotti ,  Anthony Coyle ,  Peter Kiener

    发明人： Yihong Yao ,  Bahija Jallal ,  Ricardo Cibotti ,  Anthony Coyle ,  Peter Kiener

    IPC分类号： A61K39/395 ,  C12Q1/68

    CPC分类号： C12Q1/6883 ,  A61K2039/505 ,  C07K16/249 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/76 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y02A90/22 ,  Y02A90/24 ,  Y02A90/26

    摘要： The present invention encompasses type-1 IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders.

    摘要翻译： 本发明包括1型IFN和IFNα诱导的PD标志物表达谱，试剂盒和用于鉴定这种IFNα诱导的PD标志物表达谱的方法。 I型IFN和IFNα诱导的PD标志物表达谱也可用于例如治疗患有I型IFN或IFNα介导的病症的患者的方法，监测接受治疗的患者的疾病进展的方法 结合并调节IFNα活性的试剂，将患者鉴定为接受结合并中和IFNα活性的治疗剂的候选物，以及诊断或提供具有IFNα诱导的病症的患者的预后。

    INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
    17.
    发明申请
    INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS 审中-公开
    干扰素诱导的药物动力学标记

    公开(公告)号：US20110287022A1

    公开(公告)日：2011-11-24

    申请号：US12999626

    申请日：2009-06-19

    申请人： Yihong Yao ,  Bahija Jallal ,  Ricardo Cibotti ,  Anthony Coyle ,  Peter Kiener ,  Barbara White

    发明人： Yihong Yao ,  Bahija Jallal ,  Ricardo Cibotti ,  Anthony Coyle ,  Peter Kiener ,  Barbara White

    IPC分类号： A61K39/395 ,  C40B30/04 ,  A61P29/00 ,  A61P17/06 ,  A61P19/02 ,  G01N33/53 ,  C12Q1/02

    CPC分类号： C07K16/249 ,  A61K2039/505 ,  C07K2317/76 ,  G01N2800/205 ,  G01N2800/56 ,  G01N2800/60

    摘要： The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognoses to patients having IFNα-induced disorders.

    摘要翻译： 本发明包括I型IFN和IFNα诱导的PD标志物表达谱，试剂盒和用于鉴定这种IFNα诱导的PD标志物表达谱的方法。 I型IFN和IFNα诱导的PD标志物表达谱也可用于例如治疗患有I型IFN或IFNα介导的病症的患者的方法，监测接受治疗的患者的疾病进展的方法 结合并调节IFNα活性的试剂，鉴定患者作为接受结合并中和IFNα活性的治疗剂的候选物，以及诊断或提供具有IFNα诱导的病症的患者的预后。

    IL-33 IN INFLAMMATORY DISEASE
    19.
    发明申请
    IL-33 IN INFLAMMATORY DISEASE 审中-公开
    炎症性疾病中的IL-33

    公开(公告)号：US20100260770A1

    公开(公告)日：2010-10-14

    申请号：US12600548

    申请日：2008-05-19

    申请人： Anthony Coyle

    发明人： Anthony Coyle

    IPC分类号： A61K39/395 ,  A61K38/00 ,  C07K16/24 ,  C07K14/00

    CPC分类号： C07K16/244 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2318/20

    摘要： The present invention encompasses IL-33 specific binding polypeptides and compositions comprising IL-33 specific binding polypeptides, e.g., antibodies and monomer/multimer domain polypeptides. The invention also encompasses methods employing the IL-33 specific binding polypeptides to treat diseases and disorders such as asthma.

    摘要翻译： 本发明包括IL-33特异性结合多肽和包含IL-33特异性结合多肽（例如抗体和单体/多聚体结构域多肽）的组合物。 本发明还包括使用IL-33特异性结合多肽来治疗疾病和病症如哮喘的方法。